Immunoglobulin Market 2020 Comprehensive Analysis On Revenues, Market Share, Strategies, Growth Rate, Technological Developments

Rising at a CAGR of 7.0% between 2018 and 2025, the global immunoglobulins market is forecast to remain strong through the forecast period. Fortune Business Insights in a report, titled "IMMUNOGLOBULINS: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2018-2025" states that the global market was worth US$ 10,750.0 Mn in 2017. The market is further expected to reach US$ 18,378.0 Mn by the end of 2025.

Highlights of the Report:

o In-depth analysis of various insights, namely, Immunoglobulin Market trends, growth drivers, opportunities, and other related challenges.
o Comprehensive details of key market players, their core competencies, and Immunoglobulin Market share.
o The potency of suppliers and buyers to make better business decisions.
o Lists out the market size in terms of volume.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/intravenous-immunoglobulins-market-100593

Key Players Operating in The Immunoglobulin Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

o CSL Behring
o Grifols, S.A.
o Kedrion S.p.A
o Octapharma
o Bio Products Laboratory Ltd.
o Biotest AG
o China Biologic Products Holdings, Inc.
o LFB SA and Shanghai RAAS Blood Products Co., Ltd.

Upgrade in Intervention Technology to Propel Growth

The increasing cases of chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI) are the major factors anticipated to drive the global immunoglobulins market. Furthermore, technological upgrades in the administration methods are likely to fuel the demand for immunoglobulins test and structure.

CUVITRU, a subcutaneous immunoglobulin introduced by Shire to facilitate the treatment of primary immunodeficiency, is the only 20% subcutaneous immunoglobulin in the U.S. without proline. Such launches are likely to enable growth in the global immunoglobulins market.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunoglobulins-market-100571

However, high costs associated with immunoglobulins and side-effects associated with immunoglobulins are a few key factors that may restrain the market.

In terms of region, North America is foreseen to emerge dominant over the forecast period. The region also held a major share in the market in 2017. The North America immunoglobulins market was worth US$ 6,291.5 Mn in 2017. Immunoglobulin is the most popular treatment available for various immune disorders. Moreover, the number of patients in the region is increasing. These factors are anticipated to contribute towards market growth.

Detailed Table of Content:
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Pipeline Analysis
4.2. Overview of Regulatory Scenario by Key Regions
4.3. Key Industry Developments
4.4. Number of Primary Immunodeficiency (PI) Patients by Key Countries
4.5. Overview of Reimbursement Scenario
5. Global Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast - By Route of Administration
5.2.1. Intravenous (IV)
5.2.2. Subcutaneous (SC)
5.3. Market Analysis, Insights and Forecast - By Indication
5.3.1. Primary Immunodeficiency
5.3.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.3.3. Guillain-Barré Syndrome (GBS)
5.3.4. Immune Thrombocytopenic Purpura (ITP)
5.3.5. Multifocal Motor Neuropathy (MMN)
5.3.6. Others
5.4. Market Analysis, Insights and Forecast - By Form
5.4.1. Liquid
5.4.2. Lyophilized
5.5. Market Analysis, Insights and Forecast - By End User
5.5.1. Hospitals
5.5.2. Clinics
5.5.3. Homecare
5.6. Market Analysis, Insights and Forecast - By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia Pacific
5.6.4. Latin America
5.6.5. Middle East & Africa
6. North America Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis - By Route of Administration
6.2.1. Intravenous (IV)
6.2.2. Subcutaneous (SC)
6.3. Market Analysis - By Indication
6.3.1. Primary Immunodeficiency
6.3.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6.3.3. Guillain-Barré Syndrome (GBS)
6.3.4. Immune Thrombocytopenic Purpura (ITP)
6.3.5. Multifocal Motor Neuropathy (MMN)
6.3.6. Others
6.4. Market Analysis - By Form
6.4.1. Liquid
6.4.2. Lyophilized
6.5. Market Analysis - By End User
6.5.1. Hospitals
6.5.2. Clinics
6.5.3. Homecare
6.6. Market Analysis - By Country
6.6.1. U.S.
6.6.2. Canada
7. Europe Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis - By Route of Administration
7.2.1. Intravenous (IV)
7.2.2. Subcutaneous (SC)
7.3. Market Analysis - By Indication
7.3.1. Primary Immunodeficiency
7.3.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7.3.3. Guillain-Barré Syndrome (GBS)
7.3.4. Immune Thrombocytopenic Purpura (ITP)
7.3.5. Multifocal Motor Neuropathy (MMN)
7.3.6. Others
7.4. Market Analysis - By Form
7.4.1. Liquid
7.4.2. Lyophilized
7.5. Market Analysis - By End User
7.5.1. Hospitals
7.5.2. Clinics
7.5.3. Homecare
7.6. Market Analysis - By Country/ Sub-Region
7.6.1. U.K.
7.6.2. Germany
7.6.3. France
7.6.4. Spain
7.6.5. Italy
7.6.6. Scandinavia
7.6.7. Rest of Europe
8. Asia Pacific Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis - By Route of Administration
8.2.1. Intravenous (IV)
8.2.2. Subcutaneous (SC)
8.3. Market Analysis - By Indication
8.3.1. Primary Immunodeficiency
8.3.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
8.3.3. Guillain-Barré Syndrome (GBS)
8.3.4. Immune Thrombocytopenic Purpura (ITP)
8.3.5. Multifocal Motor Neuropathy (MMN)
8.3.6. Others
8.4. Market Analysis - By Form
8.4.1. Liquid
8.4.2. Lyophilized
8.5. Market Analysis - By End User
8.5.1. Hospitals
8.5.2. Clinics
8.5.3. Homecare
8.6. Market Analysis - By Country/ Sub-Region
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. Southeast Asia
8.6.6. Rest of Asia Pacific
Continued...

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/immunoglobulins-market-100571

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.